Insurance Prior Authorization for RA: A Survival Guide

You have RA. Your rheumatologist found the biologic that works for you. You've been waiting weeks — or you've been on it and it's working — and then you get a letter from your insurance company that says something like "prior authorization required" or "not medically necessary" or "step therapy required first."

This is not a medical decision. It is an administrative one, designed — let's be direct — to reduce costs by creating friction that causes patients to give up. The good news is that prior auth denials are often reversed on appeal. You just have to know how to fight them.

What Prior Authorization Actually Is

Prior authorization (PA) is a process where your insurance company requires your doctor to get approval before they'll cover a specific drug, procedure, or service. For RA biologics, PA is nearly universal. Every major insurer has it.

The stated purpose is to ensure the drug is medically appropriate. The actual effect is to create a barrier that reduces drug utilization — some patients give up, some doctors don't resubmit, some people wait so long they try a less effective (cheaper) alternative first.

Step Therapy: The Most Frustrating Version

"Step therapy" (sometimes called "fail first") is the requirement that you try and fail cheaper drugs before your insurance will approve the expensive one. For RA, this typically means your insurer won't approve a biologic until you've tried methotrexate — and potentially one or two other conventional DMARDs — for a defined period and "failed" them (meaning they didn't work adequately or caused intolerable side effects).

The problem: your rheumatologist may have very good medical reasons to start you on a biologic directly. Early aggressive treatment improves long-term outcomes. Waiting to fail conventional therapy is not always in your clinical interest. This is a tension between your insurer's financial interest and your medical needs.

Why PA Gets Denied (Common Reasons)

• Step therapy not completed: Insurer says you haven't tried conventional DMARDs first.
• Documentation incomplete: The PA request didn't include enough clinical detail — disease activity scores, lab results, prior drug trials.
• Wrong diagnosis codes: A coding mismatch between the diagnosis on the PA form and what the insurer's criteria requires.
• Drug not on formulary: Your insurer prefers a different biologic for formulary/rebate reasons.
• Non-preferred drug: Your drug is on the formulary but at a tier that requires PA and the criteria aren't met.
• Off-label use: The biologic is being used for a different indication (though most RA biologics have broad FDA approvals).

How to Fight a Prior Auth Denial: Step by Step

Step 1: Get the Denial in Writing

You're entitled to a written denial with the specific reason. If you got a verbal denial or a vague letter, call the insurance company and ask for the specific clinical criteria your drug failed to meet, and the specific code or section of their coverage policy they're applying. Write this down.

Step 2: Talk to Your Rheumatologist's Office Immediately

This is critical. Many PA denials are resolved at this stage — not by you, but by your rheumatologist's office resubmitting with more documentation. Tell them you were denied and why. Ask:

• "Can you resubmit with additional documentation?"
• "Does your office have a PA specialist or patient coordinator who handles these?"
• "What clinical information would strengthen the appeal?"

Good rheumatology practices deal with PA every day. They know what documentation gets approvals. Make sure they know you were denied and that you want to appeal.

Step 3: File a Formal Appeal

Every insurer is required to have an appeals process. The first level is usually an internal appeal reviewed by the same insurer. File this even if it feels futile — it's a required step before escalating.

Your appeal should include:

• A letter from your rheumatologist explaining the medical necessity. This is the most important document. It should include your disease activity score (DAS28 or CDAI), joint counts, lab values (RF, anti-CCP, CRP/ESR), functional impairment, prior drug trials and why they failed or were not appropriate, and a specific statement that the requested treatment is medically necessary.
• Copies of relevant office visit notes documenting your disease history.
• Any relevant clinical guidelines (ACR guidelines recommend biologics for moderate-to-severe RA — citing these in your appeal matters).
• A personal statement describing your functional limitations and daily impact.

Step 4: Request an Expedited Review If Medically Urgent

If your condition is serious and waiting for standard review (which can take weeks) would significantly harm you, request an expedited review. Insurers are required to decide within 72 hours for expedited reviews. Your rheumatologist needs to document the urgency in writing.

Step 5: External Review

If your internal appeal is denied, you have the right to an external independent review — a review by a medical professional who works for neither you nor the insurer. Under the ACA, most plans are required to offer external review. This is often where reversals happen, because external reviewers are physicians, not claims processors, and they frequently side with doctors on medical necessity.

Request external review in writing immediately after your internal appeal is denied. There's a time limit (usually 180 days from denial, but confirm with your state).

Step 6: Your State Insurance Commissioner

File a complaint with your state insurance commissioner. This is a last resort, but it has teeth. Insurance companies do not like regulator involvement. Even filing a complaint sometimes prompts reconsideration. Go to your state's insurance department website and file online.

Step Therapy Override Laws

Many states now have step therapy override laws that require insurers to waive step therapy requirements under specific circumstances — for example, if a patient has already tried and failed the required drugs in the past, if the required drug is contraindicated, or if the physician documents clinical reasons the step is inappropriate. As of 2025, over 30 states have such laws.

Ask your rheumatologist's office if your state has step therapy override protections and whether you qualify. This can fast-track an exception.

Practical Tips That Make a Difference

• Document everything. Date and time of every phone call. Names of people you spoke with. Reference numbers.
• Be persistent but professional. Insurance staff are following scripts. The person on the phone didn't design the policy. Ask for supervisors when needed, but stay calm.
• Use the manufacturer's support program. Drug companies like AbbVie (myAbbVie Assist), Pfizer (RxPathways), and Eli Lilly (Lilly Cares) have dedicated teams to help patients navigate PA for their drugs. Call them. They know your insurer's criteria inside and out and can help coordinate with your doctor's office.
• Ask about a bridge supply. If you're waiting on appeal, ask the manufacturer's patient support program if they can provide a short-term bridge supply of medication while the appeal is pending.
• Involve a patient advocate. The Patient Advocate Foundation (patientadvocate.org) offers case managers who help navigate PA and appeals at no cost. Worth calling if you're getting nowhere.

What Success Looks Like

First-level internal appeals are reversed about 40% of the time when submitted with strong physician documentation. External reviews reverse denials 40–60% of the time in some studies. Combined, a well-documented appeal and external review process succeeds more often than it fails.

It is exhausting and shouldn't require this much effort. But it is winnable. Don't accept the first denial as a final answer.